Literature DB >> 31855281

EZH2 enhances expression of CCL5 to promote recruitment of macrophages and invasion in lung cancer.

Lilong Xia1, Xinhai Zhu1, Lei Zhang1, Yanhui Xu1, Guoping Chen1, Jing Luo1.   

Abstract

EZH2 (enhancer of zeste homolog 2) regulates epigenetic gene silencing and functions as critical regulators in various tumor progression. Macrophages infiltration promotes cancer development via stimulating tumor cell migration and invasion. However, the effect of EZH2 on macrophages infiltration, cell invasion, and migration of lung cancer remains to be investigated. In this study, we found that knockdown of EZH2 inhibited macrophages chemotaxis and decreased chemokine ligand 5 (CCL5). Wound-healing and transwell assays results showed that migration and invasion of lung cancer cells was inhibited by EZH2 deletion. Moreover, EZH2 overexpression increased CCL5 expression. Loss-of functional assay indicated that the promotion ability of EZH2 on macrophages chemotaxis was inhibited by CCL5 knockdown. Mechanistically, the promotion ability of EZH2 on cell migration and invasion of lung cancer was also inhibited by CCL5 knockdown. The in vivo subcutaneous xenotransplanted tumor model also revealed that silence of EZH2 suppressed lung cancer metastasis and macrophages infiltration via regulation of CCL5. In conclusion, our findings indicated that EZH2 promoted lung cancer metastasis and macrophages infiltration via upregulation of CCL5, which might be the underlying mechanism of EZH2-induced lung cancer cell progression.
© 2019 International Union of Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  CCL5; EZH2; chemokines; lung cancer; macrophage recruitment; metastasis

Mesh:

Substances:

Year:  2020        PMID: 31855281      PMCID: PMC7818479          DOI: 10.1002/bab.1875

Source DB:  PubMed          Journal:  Biotechnol Appl Biochem        ISSN: 0885-4513            Impact factor:   2.431


  37 in total

1.  Chemokines and cancer

Authors: 
Journal:  Arch Pathol Lab Med       Date:  2000-04       Impact factor: 5.534

Review 2.  Degradomics: systems biology of the protease web. Pleiotropic roles of MMPs in cancer.

Authors:  Christopher M Overall; Richard A Dean
Journal:  Cancer Metastasis Rev       Date:  2006-03       Impact factor: 9.264

3.  Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.

Authors:  Wei Qi; HoMan Chan; Lin Teng; Ling Li; Shannon Chuai; Ruipeng Zhang; Jue Zeng; Min Li; Hong Fan; Ying Lin; Justin Gu; Ophelia Ardayfio; Ji-Hu Zhang; Xiaoxia Yan; Jialuo Fang; Yuan Mi; Man Zhang; Tao Zhou; Grace Feng; Zijun Chen; Guobin Li; Teddy Yang; Kehao Zhao; Xianghui Liu; Zhengtian Yu; Chris X Lu; Peter Atadja; En Li
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-10       Impact factor: 11.205

4.  CCL5 increases lung cancer migration via PI3K, Akt and NF-kappaB pathways.

Authors:  Chun-Yin Huang; Yi-Chin Fong; Chun-Yi Lee; Meng-Yi Chen; Hsiao-Chi Tsai; Horng-Chaung Hsu; Chih-Hsin Tang
Journal:  Biochem Pharmacol       Date:  2008-11-25       Impact factor: 5.858

5.  The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time.

Authors:  Junliang Ma; Lunxu Liu; Guowei Che; Nanbin Yu; Fuqiang Dai; Zongbing You
Journal:  BMC Cancer       Date:  2010-03-25       Impact factor: 4.430

Review 6.  Targeting tumor-infiltrating macrophages to combat cancer.

Authors:  Roheena Z Panni; David C Linehan; David G DeNardo
Journal:  Immunotherapy       Date:  2013-10       Impact factor: 4.196

7.  Mast cell and macrophage chemokines CXCL1/CXCL2 control the early stage of neutrophil recruitment during tissue inflammation.

Authors:  Katia De Filippo; Anne Dudeck; Mike Hasenberg; Emma Nye; Nico van Rooijen; Karin Hartmann; Matthias Gunzer; Axel Roers; Nancy Hogg
Journal:  Blood       Date:  2013-05-03       Impact factor: 22.113

8.  Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer.

Authors:  Haikuo Zhang; Jun Qi; Jaime M Reyes; Lewyn Li; Prakash K Rao; Fugen Li; Charles Y Lin; Jennifer A Perry; Matthew A Lawlor; Alexander Federation; Thomas De Raedt; Yvonne Y Li; Yan Liu; Melissa A Duarte; Yanxi Zhang; Grit S Herter-Sprie; Eiki Kikuchi; Julian Carretero; Charles M Perou; Jacob B Reibel; Joshiawa Paulk; Roderick T Bronson; Hideo Watanabe; Christine Fillmore Brainson; Carla F Kim; Peter S Hammerman; Myles Brown; Karen Cichowski; Henry Long; James E Bradner; Kwok-Kin Wong
Journal:  Cancer Discov       Date:  2016-06-16       Impact factor: 39.397

9.  High infiltration of tumor-associated macrophages in triple-negative breast cancer is associated with a higher risk of distant metastasis.

Authors:  Zhong-Yu Yuan; Rong-Zhen Luo; Rou-Jun Peng; Shu-Sen Wang; Cong Xue
Journal:  Onco Targets Ther       Date:  2014-08-21       Impact factor: 4.147

Review 10.  Targeting the CCL2-CCR2 signaling axis in cancer metastasis.

Authors:  Su Yin Lim; Arseniy E Yuzhalin; Alex N Gordon-Weeks; Ruth J Muschel
Journal:  Oncotarget       Date:  2016-05-10
View more
  17 in total

1.  Prediction of Prognosis in Patients with Hepatocellular Carcinoma Based on Molecular Subtypes of Immune Genes.

Authors:  Suming Du; Jinhui Xu; Jiajia Shen; Xiaojin Zhang; Huanzhang Hu; Xinghua Huang
Journal:  Gastroenterol Res Pract       Date:  2022-06-28       Impact factor: 1.919

2.  EZH2 inhibition: a promising strategy to prevent cancer immune editing.

Authors:  Ning Kang; Mark Eccleston; Pier-Luc Clermont; Maryam Latarani; David Kingsley Male; Yuzhuo Wang; Francesco Crea
Journal:  Epigenomics       Date:  2020-09-17       Impact factor: 4.778

Review 3.  EZH2: a novel target for cancer treatment.

Authors:  Ran Duan; Wenfang Du; Weijian Guo
Journal:  J Hematol Oncol       Date:  2020-07-28       Impact factor: 17.388

Review 4.  Research trends in pharmacological modulation of tumor-associated macrophages.

Authors:  Neng Wang; Shengqi Wang; Xuan Wang; Yifeng Zheng; Bowen Yang; Juping Zhang; Bo Pan; Jianli Gao; Zhiyu Wang
Journal:  Clin Transl Med       Date:  2021-01

Review 5.  The Pharmacological TAILS of Matrix Metalloproteinases and Their Inhibitors.

Authors:  Nabangshu Das; Colette Benko; Sean E Gill; Antoine Dufour
Journal:  Pharmaceuticals (Basel)       Date:  2020-12-31

Review 6.  Revisiting Lung Cancer Metastasis: Insight From the Functions of Long Non-coding RNAs.

Authors:  Peng Huang; Shaomi Zhu; Xin Liang; Qinxiu Zhang; Chi Liu; Linjiang Song
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

Review 7.  CCL5/CCR5 axis in human diseases and related treatments.

Authors:  Zhen Zeng; Tianxia Lan; Yuquan Wei; Xiawei Wei
Journal:  Genes Dis       Date:  2021-08-26

8.  Silencing of MBD2 and EZH2 inhibits the proliferation of colorectal carcinoma cells by rescuing the expression of SFRP.

Authors:  Yang Xie; Feng Wang; Jun Yu; Jing Zhang; Yuting Liu; Mengying Li; Jian Qi
Journal:  Oncol Rep       Date:  2021-10-07       Impact factor: 3.906

9.  miR-101-3p Serves as a Tumor Suppressor for Renal Cell Carcinoma and Inhibits Its Invasion and Metastasis by Targeting EZH2.

Authors:  Yunze Dong; Yuchen Gao; Tiancheng Xie; Huan Liu; Xiangcheng Zhan; Yunfei Xu
Journal:  Biomed Res Int       Date:  2021-07-07       Impact factor: 3.411

10.  LINC00662 Promotes Oral Squamous Cell Carcinoma Cell Growth and Metastasis through miR-144-3p/EZH2 Axis.

Authors:  Yongmei Yao; Yang Liu; Fengqin Jin; Zhaohua Meng
Journal:  Yonsei Med J       Date:  2021-07       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.